A multistep docking and scoring protocol for congeneric series: Implementation on kinase DFG-out type II inhibitors by Granadino Roldán, José M. et al.
 1 
A	multistep	docking	and	scoring	protocol	for	congeneric	series:	Implementation	on	kinase	
DFG-out	type	II	inhibitors	
José	M.	Granadino-Roldán1,*,	Andrés	Garzón2,	Patricia	Gomez-Gutierrez3,	Ignacio	Pasamontes-Funez4,	M.	
Santos	Tomas5,	Jaime	Rubio-Martinez4,*	
1	Departamento	de	Química	Física,	Facultad	de	Ciencias	Experimentales,	Universidad	de	Jaén,	Campus	“Las	Lagunillas”	s/n,	23071,	
Jaén,	Spain	
2	Departamento	de	Química	Física,	Facultad	de	Farmacia,	Universidad	de	Castilla-La	Mancha,	Paseo	de	los	Estudiantes,	s/n,	02071,	
Albacete,	Spain	
3	Department	of	Chemical	Engineering,	Universitat	Politecnica	de	Catalunya,	ETSEIB.	Av.	Diagonal,	647,	08028	Barcelona,	Spain	
4 Departament	de	Química	Física,	Universitat	de	Barcelona	(UB)	and	the	Institut	de	Recerca	en	Quimica	Teorica	i	Computacional	
(IQTCUB),	Martí	i	Franqués	1,	08028	Barcelona,	Spain	
5	Department	of	Architecture	Technology,	Universitat	Politecnica	de	Catalunya,	Av.	Diagonal	649,	08028	Barcelona,	Spain 
	
Abstract	
Aim:	Re-scoring	of	docking	binding	poses	can	significantly	improve	molecular	docking	results.	Our	aim	was	to	evaluate	
post-processing	docking	protocols	in	order	to	determine	the	most	suitable	methodology	for	the	study	of	the	binding	
of	congeneric	compounds	to	protein	kinases.	Materials	&	Methods:	Diverse	 ligand-receptor	poses	generated	after	
docking	were	submitted	to	different	relaxation	protocols.	MMPB(GB)SA	approach	was	applied	for	the	evaluation	of	
the	binding	affinity	of	complexes	obtained.	The	performance	of	various	MMPB(GB)SA	methodologies	was	compared.	
Results:	The	inclusion	of	a	post-processing	protocol	after	docking	enhances	the	quality	of	the	results,	although	the	
best	methodology	is	system-dependent.	Conclusion:	An	examination	of	the	interactions	established	has	allowed	us	to	
suggest	useful	modifications	for	the	design	of	new	type	II	inhibitors.		
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More	than	500	protein	kinases	compose	the	so-called	human	kinome,	whose	members	play	a	fundamental	role	 in	
signalling	pathways	needed	 to	 control	 cellular	processes	 such	as	metabolism,	 transcription,	 cell	 cycle	progression,	
cytoskeletal	rearrangement,	apoptosis	and	differentiation	[1].	Kinases	transfer	the	γ-phosphate	of	ATP	to	a	substrate	
protein,	regulating	this	way	the	activity	of	many	enzymes.	Dysfunction	of	kinases	has	been	associated	with	a	number	
of	diseases,	among	them	remarkably	cancer	[2].	The	inhibition	of	deregulated	protein	kinases	has	thus	been	proposed	
as	a	target	against	cancer,	and	considerable	efforts	are	being	dedicated	to	develop	selective	small	molecule	kinase	
inhibitors	[3].	A	way	to	impede	γ-phosphate	transfer	is	to	prevent	ATP	from	binding	to	the	kinase	in	its	conserved	ATP	
binding	domain.		
Kinase	inhibitors	can	be	classified	depending	on	where	they	bind	and	how	they	block	kinase	catalysis.	Most	kinase	
inhibitors	are	ATP	competitive,	binding	within	the	ATP	binding	site	in	the	protein	DFG-in	active	conformation,	a	cleft	
between	the	two	lobes	of	the	kinase	catalytic	domain.	These	are	type	I	inhibitors,	which	typically	lack	selectivity	against	
one	particular	kinase	due	to	the	highly	conserved	ATP	binding	site	among	the	kinome	[4].	To	overcome	this	limitation,	
current	drug	discovery	efforts	aim	to	develop	allosteric	kinase	inhibitors,	most	of	them	targeting	the	DFG-out	inactive	
conformation.	These	DFG-out	inhibitors	stabilize	the	inactive	conformation	preventing	ATP	from	binding	[5].	When	
the	inhibitor	binds	partially	to	the	ATP	binding	site	and	partially	to	an	allosteric	site	it	is	called	a	type	II	inhibitor,	while	
compounds	binding	completely	in	allosteric	sites	are	called	type	III	inhibitors	[6].	A	unified	view	of	allostery	has	been	
described	recently	[7].	
Some	 allosteric	 inhibitors	 have	 been	 approved	 and	 others	 are	 in	 the	 early	 stages	 of	 clinical	 trials.	 Gleevec®	 was	
approved	in	2002	for	the	treatment	of	chronic	myeloid	leukaemia	and	gastrointestinal	stromal	tumours,	being	the	first	
compound	proven	to	inhibit	a	kinase	by	binding	the	DFG-out	allosteric	site	[8].	Nexavar®	was	approved	in	2005	for	the	
treatment	 of	 renal	 cell	 carcinoma	 and	 hepatocellular	 carcinomas,	 while	 BIRB-796,	 developed	 as	 a	 treatment	 for	
rheumatoid	arthritis	and	Crohn’s	disease,	was	withdrawn	from	phase	III	clinical	trials	[9].	
Due	 to	 the	 clinical	 importance	 of	 the	 abovementioned	 compounds	 there	 exists	 an	 enormous	 interest	 on	 the	
development	of	new	similar	derivatives	able	to	overcome	possible	resistance	and	exhibiting	higher	selectivity.	Thus,	J.	
Dietrich	et	al.	[10]	synthesized	8	different	combinations	of	the	basic	skeleton	of	Gleevec®,	Nexavar®	and	BIRB-796	and	
reported	their	inhibitory	activity	against	the	B-Raf,	c-Abl	and	p38α	proteins.	The	analysis	of	the	changes	in	inhibitory	
activity	allowed	the	authors	to	extract	some	structure	activity	relationships,	although	unfortunately	no	X-ray	structure	
of	any	of	the	proteins	with	the	newly	synthesized	compounds	has	been	reported	up	to	date.	This	study	aims	to	gain	
insight	on	the	interactions	established	between	these	8	new	compounds	and	the	3	kinase	proteins.	The	analysis	of	
these	 interactions	will	 lead	 to	 a	 deeper	 knowledge	 of	 the	 structure	 activity	 relationships	 and	 to	 propose	 further	
modifications	to	improve	the	inhibitors.	
The	usual	 approximation	 to	 predict	 the	 interaction	mode	between	 a	 ligand	 and	 a	 receptor	makes	 use	 of	 docking	
methods	 based	 on	 the	 receptor	 structure,	 although	 it	 is	 well	 known	 that	 these	 methods	 suffer	 from	 serious	
deficiencies	when	trying	to	obtain	a	correlation	between	experimental	affinity	and	docking	score	for	a	set	of	ligands	
[11,	12].	One	way	to	circumvent	this	problem	arises	when	the	studied	compounds	belong	to	a	congeneric	series,	that	
is,	they	are	formed	from	modifications	to	the	same	core,	which	allows	to	suppose	that	the	core	binding	mode	has	to	
be	the	same	and	focus	the	effort	during	the	docking	procedure	in	generating	and	checking	conformations	for	the	non-
common	part	[13].	But	even	in	these	particular	cases,	there	exist	evidences	showing	that	performing	a	re-scoring	of	
the	 ligand-protein	 complexes	obtained	 through	docking,	by	means	of	a	more	accurate	methodology,	 substantially	
improves	 the	 correlation	 between	 experimental	 and	 calculated	 results	 [14,	 15].	 One	 of	 the	 most	 widely	 used	
approaches	 that	 combines	 computational	 efficiency	 and	 precision	 is	 the	Molecular	Mechanics	 Poisson	 Boltzmann	
(Generalized	Born)	Surface	Area	(MMPB(GB)SA)	method	[16].	Although	this	methodology	is	usually	applied	to	a	set	of	
structures	obtained	from	Molecular	Dynamics	(MD),	it	has	been	shown	that	its	application	to	one	structure	is	able	to	
substantially	improve	docking	results	[17,	18].		
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The	dielectric	constant,	used	by	both	GB	and	PB	methods	to	determine	the	electrostatic	contribution	to	binding,	is	
divided	into	two	parts,	i.e.	the	external	dielectric	constant	(εext)	for	the	bulk	solvent,	which	is	a	well-defined	property,	
and	the	internal	dielectric	constant	(εint).	The	latter	is	not	well	defined	because	the	ligand	and	protein	are	not	uniform	
electrostatic	media	[19].	Moreover,	it	can	be	considered	as	a	compensation	factor	for	the	interaction	that	is	neglected	
in	the	continuum	method	[19],	or	just	a	parameter	that	depends	on	the	method	and	system	being	used	[20].	Although	
the	original	formulation	of	the	MMPB(GB)SA	methodology	uses	a	value	of	1	for	εint	[16],	it	has	been	suggested	that	
results	could	improve	using	a	larger	εint	[21],	with	optimum	values	of	the	interior	dielectric	constant	varying	from	1	to	
25	[19].	The	use	of	values	lower	than	1	can	in	fact	be	considered	unrealistic	taking	into	account	its	original	physical	
definition,	although	if	one	focusses	in	considering	it	merely	as	a	parameter	to	be	adjusted	some	interesting	conclusions	
could	be	extracted.	Thus,	in	a	recent	article	by	Li	et	al.	[22],	the	authors	essay	the	use	of	a	smooth	dielectric	function	
and	vary	what	they	define	as	the	reference	dielectric	value	from	0.1	to	4.0.	
Besides,	it	is	well	known	that	entropy	calculations	dominate	the	computational	cost	[23],	so	that	entropy	is	sometimes	
calculated	only	for	a	subset	of	the	snapshots	from	the	molecular	dynamics	run.	Although	it	is	clear	that	the	term	is	
needed	to	obtain	absolute	binding	free	energies,	it	has	also	been	reported	not	to	improve	the	prediction	when	ranking	
within	a	given	set	[24,	25].	
Hence,	the	aims	of	the	present	work	are	twofold.	On	the	one	hand,	we	present	a	multi-step	protocol	composed	of	an	
initial	truncated	docking	and	subsequent	re-scoring	with	the	MMPB(GB)SA	methodology,	being	our	goal	to	compare	
between	 a	 number	 of	 options	 in	 this	 protocol	 and	 decide	 the	 most	 appropriate	 methodology	 for	 the	 study	 of	
congeneric	 compounds	of	Nexavar®,	Gleevec®	 and	BIRB-796.	 By	means	of	 different	 scoring	 functions	we	want	 to	
evaluate	the	performance	of	just	using	docking	or	re-scoring	with	different	choices.	Thus,	we	will	compare	re-scoring	
with	MMGBSA	(with	different	GB	approaches),	with	MMPBSA	(with	different	values	for	εint),	and	we	will	also	check	
the	influence	of	using	one	snapshot	for	MMPB(GB)SA	or	a	short	MD	run.	Finally,	the	influence	of	using	an	entropic	
term,	given	its	computational	cost,	will	also	be	evaluated.	
On	 the	 other	 hand,	 apart	 from	 the	 analysis	 of	 methodologies,	 we	 plan,	 once	 the	 best	 method	 for	 each	 set	 is	
determined,	analyse	 the	proposed	docked	structures	 in	order	 to	gain	 insight	 into	 those	 interactions	 that	could	be	
improved	and	those	that	should	be	avoided	to	obtain	improved	allosteric	inhibitors	of	these	protein	kinases.	
Materials	&	Methods	
Minimizations,	MD	and	MMPB(GB)SA	calculations	were	carried	out	using	the	Amber	ff99SB	force	field	for	the	proteins	
[26]	and	generalized	amber	force	field	(gaff)	[27]	for	the	ligands,	as	implemented	in	the	Amber	v.14	suite	of	programs	
[28].	Minimizations	and	MD	runs	were	performed	under	periodic	boundary	conditions	using	the	particle-mesh-Ewald	
method	[29]	for	the	treatment	of	the	long-range	electrostatic	interactions.	A	cut-off	distance	of	10	Å	was	chosen	to	
compute	the	non-bonded	interactions	and	the	solvent	was	considered	explicitly	using	TIP3P	[30]	water	molecules	with	
a	minimum	distance	from	the	edge	of	the	box	of	15	Å	and	removing	those	water	molecules	closer	than	1.8	Å	from	any	
protein	atom.	Counterions	were	added,	when	necessary,	to	neutralize	the	systems.	A	two	steps	heating	protocol	with	
an	integration	time	step	of	1	fs	has	been	used	which	includes	increasing	the	temperature	of	the	system	to	300	K	at	a	
constant	rate	of	3	K	ps-1	during	100	ps	in	the	NVT	ensemble,	and	200	ps	at	300	K	in	the	NPT	ensemble	to	adjust	density.	
After	equilibration,	a	2	fs	integration	time	step	was	used	to	run	2	ns	of	MD	at	300	K	in	the	NVT	ensemble.	
Preparation	of	the	systems	to	work	with	Amber	v.14	and	post-processing	of	the	minimization	and	MD	runs	used	the	
Antechamber,	LEaP,	cpptraj	and	MMPBSA.py	modules	of	AmberTools14	[28]	package.	Figures	were	rendered	with	
UCSF	Chimera	[31],	while	graphs	were	prepared	with	Origin	[32].	
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System	preparation	
The	five	initial	experimental	X-Ray	structures	of	the	complexes	c-Abl	with	Gleevec®,	B-Raf	with	Nexavar®,	p38α	with	
Gleevec®,	 p38α	 with	 Nexavar®,	 and	 p38α	 with	 BIRB-796	 were	 obtained	 from	 the	 Protein	 Data	 Bank	 [33]	
(http://www.rcsb.org),	with	codes	1IEP	[34],	1UWJ	[35],	3HEC	[36],	3HEG	[36]	and	1KV2	[37],	respectively.	
Missing	residues	for	the	three	p38α	structures	were	taken	from	the	solved	structure	with	PDB	code	1W82	[38].	On	the	
other	hand,	the	B-Raf	structure	was	modelled	as	described	in	reference	[25].	Parameters	and	charges	for	all	the	ligands	
were	obtained	using	Antechamber	[28]	with	the	gaff	force	field	[27]	and	partial	charges	derived	through	the	AM1-BCC	
method	[39,	40],	which	is	recommended	in	large-scale	calculations	because	of	its	efficiency.	All	complexes	were	energy	
minimized	to	avoid	possible	steric	clashes	following	a	three	steps	protocol	which	first	minimizes	only	water	molecules	
and	counterions	 (1000	steepest	descent	steps),	 later	also	side	chains	are	allowed	to	move	(1000	steepest	descent	
steps),	and	ends	with	5000	(steepest	descent)	steps	allowing	the	whole	system	to	move.	
Docking	
The	docking	procedure	used	as	target	proteins	the	five	models	prepared	as	explained	before,	and	as	ligands	Gleevec®,	
Nexavar®	and	BIRB-796,	along	with	the	8	ligands	synthesized	by	J.	Dietrich	et	al.	[10]	(see	Figure	1).	Due	to	the	fact	
that	the	ligands	studied	share	a	similar	core	(congeneric	series,	see	Figure	2),	we	used	a	simplified	approach	for	the	
conformational	positional	search	of	the	ligands	in	the	protein	binding	site.	We	assume	that	the	common	core	of	the	
ligands	will	 interact	with	each	protein	in	a	similar	way	as	the	experimental	one	for	each	of	the	five	receptors	 [13],	
without	 change	 to	 a	 different	 position.	 Thus,	 the	 substructures	 of	 the	 compounds	 highlighted	 in	 Figure	 2	 were	
superimposed,	 using	 a	 script	 written	 by	 the	 development	 team	 of	 the	 MOE	 software	 [41],	 to	 the	 experimental	
structures	avoiding	this	way	the	placement	stage	during	the	docking	process.	After	this,	MOE	[41]	was	used	to	generate	
the	conformations	of	the	rotatable	bonds	using	the	systematic	approach	and	forbidding	rotation	for	the	common	core	
substructure.	Once	the	conformational	ensemble	for	each	ligand-protein	complex	was	generated,	the	prediction	of	
the	 ligand-protein	binding	energy	was	conducted	with	MOE	[41],	avoiding	the	placement	stage	and	using	as	 initial	
scoring	 function	 the	 Affinity	 dG	 energy	 function.	 Next,	 in	 order	 to	 introduce	 side	 chain	 flexibility	 in	 the	 receptor	
description,	a	Force	Field	post-placement	methodology	was	used,	which	allows	side	chains	located	less	than	10	Å	from	
the	ligand	to	move	freely.	As	a	result,	we	obtained	55	(five	X-Ray	structures	and	eleven	ligands)	sets	of	ligand-protein	
conformations	ranked	in	energy,	each	one	composed	of	20	different	conformations.		
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Figure	 1:	 Ligands	 studied	 in	 this	 work,	 highlighting	 with	 colours	 the	 origin	 of	 each	 part	 for	 those	 synthesized	 in	
reference	[10]	
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Figure	2:	Gleevec®,	Nexavar®	and	BIRB-796	highlighting	 in	 red	 the	common	substructure	used	during	 the	docking	
procedure	
Rescoring	
Minimization	
The	six	poses	showing	best	interaction	energy	according	to	MOE,	among	the	20	obtained	from	the	docking	for	each	
ligand-protein	 set,	 having	 also	 a	 root	 mean	 square	 deviation	 (rmsd)	 between	 them	 higher	 than	 0.05	 Å,	 were	
subsequently	subjected	to	a	minimization	following	the	already	explained	protocol.	
Binding	free	energy	calculation	
Binding	 free	energies	 (ΔGbind)	were	calculated	using	 the	MMPB(GB)SA	algorithms	 implemented	 in	 the	MMPBSA.py	
program	[42].	Thus,	the	binding	free	energy	is	computed	as	the	difference:	∆𝐺#$%& = ∆𝐺()*+,-. − (∆𝐺+1)2-$% + ∆𝐺,$45%&)				(1)	
and	each	term	can	be	estimated	as	follows:	∆𝐺 = 	∆𝐺8 + 	∆𝐺9), = ∆𝐻;;8 − 𝑇∆𝑆8 + ∆𝐺9), 				(2)	
with	 the	 0	 superscript	 referring	 to	 values	 in	 vacuo,	 being	∆𝐻;;8 the	molecular	mechanics	 free	 energy,	∆𝐺9), 	 the	
solvation	free	energy,	and	𝑇∆𝑆8	the	entropic	contribution.	The	molecular	mechanics	energy	is	in	turn	calculated	as	a	
sum	of	the	internal,	electrostatic	and	van	der	Waals	interactions:	∆𝐻;;8 = 	∆𝐻$%28 + 	∆𝐻-,-8 + ∆𝐻>&?8 			(3)	
while	the	solvation	free	energy	is	obtained	from	the	polar	and	nonpolar	contributions:	∆𝐺9), = 	∆𝐺-,-,9), + ∆𝐺%)%+),,9), 				(4)	
The	polar	contribution	to	solvation	free	energy	can	be	calculated	by	solving	the	Poisson-Boltzmann	(PB)	equation	[43]	
in	the	case	of	MMPBSA,	or	by	using	the	Generalized	Born	(GB)	approach	[44]	for	MMGBSA.	
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Finally,	the	nonpolar	contribution	to	solvation	free	energy	is	determined	through	the	solvent	accessible	area	(SASA,	
Å2)	according	to:	 ∆𝐺%)%+),,9), = 𝛾𝑆𝐴𝑆𝐴 + 𝑏				(5)	
where	𝛾	stands	for	the	surface	tension	(0.0378	kcal	mol-1	Å-2)	and	𝑏	is	a	constant	(-0.5692	kcal	mol-1).	
The	entropic	term	was	calculated	using	normal-mode	analysis	with	default	values	using	the	MMPBSA.py	program	[42].	
Taking	into	account	the	high	computational	cost	of	this	approach	and	the	high	number	of	systems	to	be	evaluated	this	
calculation	was	only	performed	in	the	case	of	the	1-snapshot	approach	(see	below).	
In	order	to	evaluate	the	performance	of	different	MMPB(GB)SA	approaches	we	have	explored	a	set	of	options.	First,	
we	ran	MMPBSA	and	MMGBSA	on	each	of	the	minimized	poses	and	ranked	them	according	to	MMPBSA	with	εint=1.	
The	three	best	poses	were	then	subjected	to	a	2	ns	MD	run	from	which	we	obtained	ΔGbind	values	for	the	first	1	ns	and	
the	whole	trajectory	using	MMPBSA	(εint=1).	Second,	we	evaluated	the	influence	of	εint		on	the	1-snapshot	approach	
running	MMPBSA	with	εint	values	of	0.8,	1	and	2.	Finally,	we	evaluated	the	influence	of	the	parameters	used	for	the	
Onufriev,	Bashford,	and	Case	GB	formulation	[44]	using	options	GB=2	and	GB=5.	Binding	free	energy	decomposition	
analysis	was	performed	in	all	cases	with	option	GB=2.	
Results	&	discussion	
Comparison	of	methods	
Three	different	criteria	were	used	to	evaluate	the	performance	of	the	methodological	approaches	compared	in	this	
study.	First,	the	percentage	of	success	(%S)	is	defined	as:	
%𝑆 = EFGEHEFGEHGIFGIH				(6)	
where	TP,	 TN,	 FP	and	FN	 stand	 for	 true	positives,	 true	negatives,	 false	positives	and	 false	negatives,	 respectively.	
According	to	the	experimental	IC50	values	determined	by	J.	Dietrich	et	al.	[10]	we	can	consider	compounds	with	an	
IC50	>	104	nM	as	weak	binders.	As	in	all	cases	there	are	four	weak	binders,	we	have	determined	TP,	TN,	FP	and	FN	for	
each	set	considering	theoretical	weak	binders	those	four	compounds	with	worst	calculated	ΔGbind.		
Second,	Spearman’s	rank	correlation	coefficient,	Sp,	which	compares	the	position	of	each	compound	when	ranked	by	
calculated	binding	energy	to	its	position	when	ranked	by	its	experimental	IC50	value	[45]:	
𝑆𝑝 = 1 − L &MN%(%NOP)				(7)	
being	di	the	difference	in	rank	for	the	ith	compound	under	the	two	different	criteria.	
All	these	parameters,	together	with	the	corresponding	Pearson’s	correlation	coefficient	between	log(IC50)	and	ΔGbind,	
r,	are	presented	for	all	essayed	methods	on	the	3	different	proteins	(3	structures	in	the	case	of	p38α)	in	Tables	1	and	
1S.	
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Table	1	Scoring	parameters	obtained	for	the	different	methodologies	applied	to	the	complexes	with	B-Raf,	c-Abl,	p38α	
Gleevec®	(protein	structure	from	the	PDB	code	3HEC),	p38α	Nexavar®	(protein	structure	from	the	PDB	code	3HEG)	
and	p38α	BIRB-796	(protein	structure	from	the	PDB	code	1KV2).	S	stands	for	the	–TΔS	term.	
	 	 1	snapshot	 MD	
	 Method	 Docking	 PB	 GB	 PB	2	ns	 PB	1	ns	
	 Parameters	 	 εi=0.8	 εi=1	 εi=2	 εi=0.8+S	 εi=1+S	 εi=2+S	 5	 2	 5+S	 2+S	 εi=1	 εi=1	
Protein	 	 	             
B-Raf	 %S	 63.64	 45.45	 81.82	 100.00	 81.82	 81.82	 100.00	 63.64	 81.82	 63.64	 81.82	 81.82	 81.82	
Sp	 0.17	 -0.25	 0.46	 0.54	 0.55	 0.65	 0.67	 -0.12	 0.55	 0.59	 0.65	 0.49	 0.40	
r	 0.05	 -0.36	 0.48	 0.82	 -0.42	 0.65	 0.85	 0.19	 0.52	 0.41	 0.65	 0.62	 0.60	
c-Abl	 %S	 63.64	 63.64	 63.64	 54.55	 63.64	 63.64	 63.64	 63.64	 63.64	 63.64	 63.64	 45.45	 45.45	
Sp	 0.66	 0.57	 0.66	 -0.19	 0.54	 0.46	 -0.15	 0.52	 0.58	 0.38	 0.31	 0.69	 0.69	
r	 0.72	 0.49	 0.57	 -0.08	 0.44	 0.44	 -0.17	 0.43	 0.51	 0.29	 0.38	 0.59	 0.55	
p38⍺	Gleevec®	 %S	 63.64	 100.00	 63.64	 27.27	 100.0	 81.82	 27.27	 45.45	 63.64	 63.64	 81.82	 81.82	 81.82	
Sp	 -0.09	 0.87	 0.47	 -0.63	 0.71	 0.59	 -0.69	 -0.18	 0.21	 0.24	 0.44	 0.68	 0.64	
r	 -0.03	 0.93	 0.60	 -0.78	 0.89	 0.76	 -0.69	 0.03	 0.43	 0.48	 0.65	 0.67	 0.67	
p38⍺	Nexavar®	 %S	 81.82	 81.82	 63.64	 27.27	 81.82	 63.64	 27.27	 63.64	 63.64	 63.64	 63.64	 81.82	 81.82	
Sp	 0.20	 0.63	 0.33	 -0.33	 0.41	 0.16	 -0.45	 0.01	 0.23	 -0.13	 0.05	 0.65	 0.60	
r	 0.39	 0.63	 0.20	 -0.53	 0.49	 0.17	 -0.53	 0.03	 0.28	 0.00	 0.21	 0.57	 0.61	
p38⍺	BIRB-796	 %S	 81.82	 100.00	 63.64	 27.27	 100.0	 81.82	 27.27	 45.45	 63.64	 63.64	 63.64	 100.00	 81.82	
Sp	 0.48	 0.73	 0.52	 -0.51	 0.77	 0.73	 -0.38	 0.23	 0.60	 0.35	 0.60	 0.73	 0.76	
r	 0.64	 0.83	 0.60	 -0.52	 0.90	 0.74	 -0.45	 0.33	 -0.08	 0.45	 0.64	 0.84	 0.85	
		
Some	conclusions	can	be	extracted	from	these	data.	First,	comparison	of	the	scoring	parameters	for	1	ns	and	2	ns	MD	
runs	allow	to	suggest	 that	 these	calculations	are	converged.	Second,	 the	MD	runs	provide	better	 results	with	 few	
exceptions,	as	can	be	concluded	when	comparing	column	PB	εi=1,	one	snapshot,	with	column	for	PB	2	ns,	εi=1,	in	Table	
1.	Thus,	MD	results	are	better	for	all	the	p38α	complexes,	almost	the	same	for	B-Raf	and	slightly	worse	for	c-Abl,	as	
compared	to	using	just	one	snapshot.	Third,	there	is	consensus	in	the	fact	that	GB=2	performs	better	than	GB=5,	and	
in	 the	 fact	 that	 the	effect	 of	 adding	 the	entropic	 term	 is	 slightly	positive	 for	 the	B-Raf	 and	p38α	 sets	 and	almost	
negligible	for	the	c-Abl	set.	
In	general,	post-processing	results	are	better	than	the	docking	ones.	In	the	case	of	B-Raf	all	post-processing	methods,	
except	GB=5,	are	better	than	docking;	for	c-Abl	none	of	the	post-processing	methods	improve	the	docking	results,	
while	for	p38α	results	are	improved	in	general	when	PB	is	used	along	with	εi=0.8	or	1	(one	snapshot)	and	the	MD	runs.	
Influence	of	εi	
The	analysis	of	the	influence	of	the	interior	dielectric	constant	in	MMPBSA	results	is	a	recurrent	topic	in	literature.	This	
interior	dielectric	constant	represents	the	effect	of	the	protein	environment	and	results	are	very	sensitive	to	the	value	
used,	although	the	factors	that	determine	its	optimal	value	are	not	obvious	at	all	[21].	It	seems,	however,	to	be	a	clear	
tendency	 to	 conclude	 that	 values	 higher	 than	 the	 default	 one	 (εi=1.0)	 are	 expected	 to	 improve	 results	 [46-48].	
Moreover,	Wang	et	al.	[49],	after	analysing	54	papers	on	MMPBSA	and	MMGBSA	free	energy	calculations,	concluded	
as	a	general	guideline	that	an	εi=1	should	be	used	for	non-polar	binding	sites,	εi=2.0	for	polar	binding	sites,	and	εi=4	
when	the	binding	site	is	composed	of	charged	residues.	In	this	work,	we	have	essayed	an	interior	dielectric	constant	
higher	than	the	default	one	(εi=2.0).	Besides,	considering	εi	just	as	an	adjustable	parameter	we	additionally	checked	
the	influence	of	a	lower	value	(εi=0.8).	
Table	1	allows	to	see	that	 the	 influence	of	 the	εi	value	depends	on	the	set	studied.	Thus,	 results	 for	 the	B-Raf	set	
improve	when	εi	increases,	reaching	a	100%	of	success	and	a	Pearson’s	correlation	coefficient	of	0.85	for	εi=2	+	S.	In	
the	case	of	 the	p38α	Gleevec®	set	%S	 improves	 from	27.3%	with	εi=2.0	 to	100%	with	εi=0.8,	all	 remaining	scoring	
parameters	 following	 the	 same	 trend	 for	 all	 three	 p38α	 sets.	 Finally,	 c-Abl	 scoring	 parameters	 show	 a	 small	
dependence	with	the	εi	value	essayed.	
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In	order	to	get	a	deeper	insight	into	the	influence	of	εi	on	the	calculated	results	Table	2	renders	the	change	in	ranking	
position	of	each	of	the	11	studied	ligands	when	the	interior	dielectric	constant	increases,	along	with	the	corresponding	
experimental	ranking	[10].	In	the	case	of	B-Raf,	experimental	IC50	values	show	that	positively	charged	ligands	(1,	4,	5	
and	10)	bind	weakly,	which	is	not	predicted	with	εi=0.8,	being	compound	one	predicted	as	the	best	one	when	using	
this	interior	dielectric	constant	value.	Interestingly,	when	εi	increases	the	position	in	the	ranking	for	ligands	1	and	4	
sharply	worsens	and	they	are	correctly	ranked	as	weak	binders	for	εi	=	2.0.	The	position	in	the	ranking	of	non-charged	
ligands	does	not	show	a	clear	tendency.	Thus,	as	a	consequence	of	the	influence	of	εi	for	charged	ligands	the	global	
result	is	that	the	ranking	coefficients	improve	when	εi	increases.		
Positively	 charged	 ligands	are	also	predicted	 to	bind	weakly	 to	p38α,	and	 inversely	 to	what	was	 seen	 for	B-Raf,	 a	
decrease	in	εi	worsens	the	ranking	position	of	charged	ligands	thus	increasing	all	ranking	coefficients	from	εi=2.0	to	
εi=0.8.	Moreover,	all	four	inactive	compounds	are	correctly	ranked	as	weak	binders	for	εi	=	0.8,	except	in	the	p38α	
Nexavar®	case,	for	which	compound	11	is	predicted	to	be	inactive	instead	of	compound	10.	
c-Abl,	on	the	other	hand,	is	the	only	protein	to	which	Gleevec®,	positively	charged,	binds	strongly,	while	ligands	4	and	
5	(positively	charged),	and	ligands	3	and	7	(with	no	charge)	are	predicted	to	bind	weakly	according	to	the	IC50	values	
[10].	The	behaviour	of	charged	ligands	is	the	same	as	for	p38α,	with	ligands	1,	4,	5	and	10	being	the	best	ranked	if	εi=2	
is	 used,	 and	 the	worst	 ranked	when	 εi=0.8	 is	 used.	 The	 fact	 that	 neutral	 compounds	do	not	 follow	a	 clear	 trend,	
together	with	the	fact	that	ligand	1,	which	binds	strongly,	follows	the	same	trend	than	weak	binders,	explain	why	the	
ranking	coefficients	for	c-Abl	do	not	correlate	clearly	with	εi.	They	also	explain	why	the	c-Abl	set	results	are	worse	than	
those	for	the	other	sets.	
Table	2:	Evolution	of	the	ranking	in	binding	affinity	(from	highest	to	lowest)	with	εi	for	one-snapshot	methods	with	no	
entropy	term.	Horizontal	line	separates	strong	binders	from	weak	binders.	
B-Raf	 c-Abl	 p38α	Gleevec®	 p38α	Nexavar®	 p38α	BIRB-796	
Experimental	 εi	 Experimental	 εi	 Experimental	 εi	
Ligand	 0.8	 1.0	 2.0	 Ligand	 0.8	 1.0	 2.0	 Ligand	 0.8	 1.0	 2.0	 0.8	 1.0	 2.0	 0.8	 1.0	 2.0	
7	 1	 8	 8	 6	 8	 8	 1	 7	 3	 3	 10	 9	 9	 10	 3	 3	 10	
2	 8	 3	 3	 8	 3	 3	 4	 9	 9	 9	 1	 3	 3	 9	 8	 8	 3	
3	 3	 9	 9	 1	 6	 6	 5	 3	 6	 8	 4	 7	 10	 8	 7	 7	 5	
11	 10	 7	 6	 9	 9	 9	 10	 6	 7	 6	 5	 8	 8	 5	 9	 9	 1	
6	 9	 6	 7	 2	 7	 1	 8	 2	 8	 10	 3	 10	 7	 3	 6	 6	 4	
9	 4	 2	 2	 11	 2	 7	 3	 11	 2	 1	 9	 6	 5	 4	 11	 10	 8	
8	 7	 1	 11	 10	 11	 2	 6	 8	 11	 7	 8	 2	 2	 1	 2	 5	 9	
1	 6	 10	 10	 7	 1	 11	 9	 1	 1	 2	 6	 5	 6	 7	 10	 11	 7	
4	 2	 4	 4	 3	 10	 10	 7	 4	 10	 11	 7	 11	 1	 2	 5	 1	 6	
5	 5	 11	 1	 4	 4	 4	 2	 5	 5	 4	 2	 4	 11	 6	 1	 2	 2	
10	 11	 5	 5	 5	 5	 5	 11	 10	 4	 5	 11	 1	 4	 11	 4	 4	 11	
	
In	order	to	have	a	closer	look,	Table	2S	collects	ΔH0ele	+	ΔGele,sol	from	the	MMPBSA	calculation,	in	the	one-snapshot	
approximation	with	no	entropic	term,	for	each	of	the	proteins	and	a	representative	neutral	and	charged	ligand.	Thus,	
for	B-Raf	we	can	compare	Gleevec®	with	Nexavar®	and	see	that	the	ΔH0ele	+	ΔGele,sol	term	follows	opposite	trends	for	
Gleevec®	or	Nexavar®,	increasing	its	value	with	εi	for	the	first,	while	decreasing	it	for	the	latter,	which	correlates	with	
the	change	in	ranking	positions	seen	in	Table	2.	The	opposite	is	seen	for	p38α	Gleevec®,	while	c-Abl	shows	the	same	
trend	for	charged	or	neutral	ligands.	
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Selection	of	the	method	which	best	reproduces	the	experimental	ranking	
With	all	these	results	in	mind	it	can	now	be	decided	which	of	all	the	essayed	methods	is	able	to	reproduce	best	the	
experimental	results	and	thus	is	supposed	to	render	the	most	trustable	structures.	Our	protocol	chooses	the	best	one-
snapshot	method	and	compare	its	results	with	those	from	the	classical	MD	approach	for	each	of	the	studied	sets,	on	
the	 basis	 of	 the	 scoring	 parameters	 shown	 in	 Table	 1.	Hence,	 in	 all	 cases	we	 compare	 one	option	 using	 just	 one	
snapshot,	with	the	classical	option	of	using	a	MD	run.	One-snapshot	MMPBSA	methods	were	chosen	in	all	cases,	with	
εi	=2	+	S	for	B-Raf,	εi	=	1	for	c-Abl,	εi	=	0.8	for	p38α	Gleevec®,	εi	=	0.8	for	p38α	Nexavar®	and	εi	=	0.8	+S	for	p38α	BIRB-
796.	All	of	them	yielded	higher	or	similar	values	of	the	scoring	parameters	of	Table	1	than	the	remaining	one-snapshot	
methods.	Table	3	compares	the	experimental	ranking	of	those	ligands	considered	strong	binders	(IC50	<	104	nM)	with	
the	predicted	rankings	from	the	best	one-snapshot	method	and	with	the	predicted	raking	from	the	2	ns	MD	MMPBSA	
calculation.	Besides,	Table	3S	renders	the	same	comparison	for	those	ligands	considered	weak	binders.	Both	tables	
also	show	which	pose	is	predicted	to	exhibit	the	best	ΔGbind	for	each	of	the	MMPBSA	options	compared	in	each	case.	
As	concerns	the	B-Raf	set,	the	three	scoring	parameters	are	better	for	the	one-snapshot	method	with	εi	=2	+	S	than	
for	2	ns	MD.	We	will	later	analyse	ligand	2	(for	which	there	is	an	experimental	structure)	and	ligand	7	(the	best	ligand	
for	B-Raf	according	to	the	experimental	results).	The	binding	poses	predicted	for	these	two	ligands	are	the	same	for	
the	best	one-snapshot	and	MD	method	(see	Table	3,	pose	5	for	ligand	7	and	pose	4	for	ligand	2).	Considering	that	both	
approaches	predict	the	same	ligand	conformations	(poses)	to	be	analysed,	 it	 is	better	to	use	the	MD	run,	as	 it	will	
allow	to	have	information	about	the	strength	of	established	H-bonds.	Thus,	for	this	set	we	will	analyse	the	structures	
from	a	snapshot	extracted	after	1	ns	of	MD.	
In	 the	case	of	c-Abl,	 the	one-snapshot	method	with	εi	=	1.0	and	no	entropic	 term	exhibits	slightly	better	%S	and	r	
values,	although	worse	Sp,	than	MMPBSA	with	2	ns	of	MD.	The	interactions	established	by	c-Abl	with	ligands	1	(for	
which	there	is	an	experimental	structure)	and	6	(the	best	ligand	for	c-Abl)	will	later	be	analysed.	Taking	into	account	
the	similar	values	obtained	for	the	scoring	parameters	of	Table	1	with	both	methods,	together	with	the	fact	that	the	
ranking	of	ligand	6	is	better	reproduced	and	no	experimental	structure	is	available	for	ligand	6,	we	decided	to	analyse	
the	structure	of	pose	1	for	ligand	1	and	pose	2	for	ligand	6	with	a	snapshot	extracted	after	1	ns	of	MD	(see	Table	3).	
Table	3:	Comparison	between	the	experimental	ranking	for	strong	binders	(IC50	<	104	nM)	and	the	rankings	predicted	
from	the	best	one-snapshot	method	or	from	2	ns	of	MD	(average	values,	standard	error	in	parenthesis).	Ligands	and	
their	corresponding	pose	whose	interactions	are	analysed	later	are	shown	in	bold.	Energies	in	kcal	mol-1.	S	stands	for	
the	TΔS	term	
	 Experimental	 One	snapshot	 MD	
	 	 	 	 	 	 	
Protein	 Ligand	 IC50	(nM)	 Ligand	 Pose	 ΔGbind	 Ligand	 Pose	 ΔGbind	
B-Raf	 	 	 	 	 PB	εi=2+S	 	 	 PB	εi=1	
	 7	 <1	 8	 5	 -138.5	 8	 2	 -112.5	(0.3)	
	 2	 76.2	 3	 1	 -136.3	 9	 4	 -104.7	(0.4)	
	 3	 83.4	 9	 4	 -133.8	 7	 5	 -100.3	(0.3)	
	 11	 92.3	 6	 5	 -124.0	 6	 5	 -97.7	(0.3)	
	 6	 180.1	 7	 5	 -123.1	 3	 1	 -96.6	(0.4)	
	 9	 236.7	 2	 4	 -122.1	 2	 4	 -94.3	(0.2)	
	 8	 413.9	 11	 5	 -112.8	 10	 4	 -91.7	(0.7)	
c-Abl	 	 	 	 	 PB	εi=1.0	 	 	 	
	 6	 <1	 8	 2	 -113.32	 8	 2	 -114.7	(0.3)	
	 8	 8.6	 3	 1	 -107.12	 6	 2	 -105.0	(0.3)	
	 1	 10.8	 6	 3	 -101.77	 3	 2	 -102.8	(0.4)	
	 9	 62.6	 9	 9	 -99.91	 9	 9	 -100.4	(0.3)	
	 2	 225.9	 1	 7	 -98.45	 7	 2	 -97.7	(0.3)	
	 11	 244	 7	 2	 -92.79	 1	 1	 -95.8	(0.3)	
	 10	 572.4	 2	 2	 -87.05	 2	 2	 -88.1	(0.3)	
p38α	Gleevec®	 	 	 	 	 PB	εi=0.8	 	 	 	
	 7	 <1	 3	 5	 -91.1	 3	 6	 -108.0	(0.4)	
	 9	 <1	 9	 1	 -83.6	 9	 8	 -102.5	(0.3)	
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	 3	 4	 6	 7	 -78.5	 8	 18	 -101.7	(0.3)	
	 6	 18.4	 7	 3	 -77.8	 6	 7	 -99.8	(0.3)	
	 2	 84.8	 8	 18	 -77.0	 1	 11	 -95.0	(0.4)	
	 11	 105.5	 2	 4	 -71.1	 7	 3	 -92.5	(0.2)	
	 8	 189.3	 11	 16	 -68.9	 2	 4	 -84.0	(0.3)	
p38α	Nexavar®	 	 	 	 	 PB	εi=0.8	 	 	 	
	 7	 <1	 9	 9	 -76.6	 3	 5	 -102.7	(0.4)	
	 9	 <1	 3	 5	 -75.7	 8	 2	 -98.6	(0.4)	
	 3	 4	 7	 5	 -69.8	 9	 14	 -95.3	(0.3)	
	 6	 18.4	 8	 16	 -68.9	 7	 5	 -87.2	(0.4)	
	 2	 84.8	 10	 19	 -65.6	 6	 20	 -84.9	(0.3)	
	 11	 105.5	 6	 18	 -65.1	 5	 2	 -84.2	(0.4)	
	 8	 189.3	 2	 15	 -64.3	 2	 15	 -80.0	(0.3)	
p38α	BIRB-796	 	 	 	 	 PB	εi=0.8+S	 	 	 	
	 7	 <1	 3	 8	 -90.2	 8	 6	 -106.1	(0.6)	
	 9	 <1	 7	 3	 -82.5	 3	 8	 -104.8	(0.3)	
	 3	 4	 8	 20	 -75.1	 7	 3	 -93.9	(0.2)	
	 6	 18.4	 6	 13	 -70.6	 6	 4	 -93.4	(0.3)	
	 2	 84.8	 11	 10	 -69.1	 9	 9	 -91.6	(0.3)	
	 11	 105.5	 9	 18	 -66.5	 2	 8	 -86.4	(0.3)	
	 8	 189.3	 2	 3	 -58.4	 11	 14	 -86.3	(0.2)	
	
The	p38α-Gleevec®	complex	is	interesting	because	the	experimental	structure	describes	a	structure	with	a	ligand	that	
is	expected	to	bind	weakly	to	the	protein	(IC50	>	104	nM).	Results	from	the	best	one-snapshot	method	are	clearly	
better	than	those	from	MMPBSA	with	2	ns	of	MD	and	the	latter	also	predicts	ligand	1	to	bind	strongly	to	the	protein,	
which	is	not	reported	to	happen	according	to	the	IC50	value	(see	Table	3,	ligand	1	pose	11	has	a	predicted	ΔGbind	=	-95	
kcal	mol-1).	Consequently,	we	will	analyse	the	one-snapshot	poses	for	p38α	with	Gleevec®	(experimental	structure)	
and	ligands	7	and	9	(with	the	lowest	IC50	values).	These	poses	are	thus	(see	Tables	3	and	3S)	pose	1	for	ligand	1,	pose	
3	for	ligand	7,	and	pose	1	for	ligand	9.	
In	the	case	of	p38α	Nexavar®	the	scoring	parameters	from	the	best	one-snapshot	method	and	and	MMPBSA	with	2	ns	
of	MD	are	almost	 identical.	We	decided	 to	analyse	 the	one-snapshot	poses	as	 the	 relative	 ranking	 for	 the	 ligands	
whose	 interactions	were	going	 to	be	examined	 later	 (ligands	1,	2,	7	and	9)	matches	better	with	 the	experimental	
results	(see	Tables	3	and	3S).	According	to	this	criterion	the	poses	to	be	analysed	were	pose	6	of	ligand	1,	pose	15	of	
ligand	2,	pose	5	of	ligand	7	and	pose	9	of	ligand	9.		
Finally,	for	the	p38α	BIRB-796	structure,	the	comparison	between	the	predicted	scoring	from	the	best	one-snapshot	
with	that	from	MMPBSA	with	2	ns	of	MD	allow	us	to	choose	the	poses	predicted	by	the	first	method,	using	the	same	
arguments	than	those	for	the	p38α	Nexavar®	set.	So,	the	predicted	interactions	to	be	analysed	are	those	established	
between	the	protein	p38α	BIRB-796	and	pose	8	of	ligand	3,	pose	1	of	ligand	1,	pose	3	of	ligand	7	and	pose	18	of	ligand	
9.	
Analysis	of	the	selected	predicted	poses	
The	 analysis,	 from	 an	 energetic	 point	 of	 view,	 will	 use	 the	 different	 terms	 arising	 from	 the	 MMGBSA	 energy	
decomposition	analysis	run,	as	well	as	information	of	the	different	H-bonds	established,	for	each	of	the	methods	and	
poses	selected	as	the	most	trustable	in	section	3.3.	These	data	appear	in	Tables	4S-8S,	while	Figures	3	and	4	try	to	
focus	on	highlighting	those	residues	of	each	protein	that	interact	differently	with	each	ligand	(difference	interaction	
spectrum),	 and	 on	 visualizing	 the	 polar	 or	 non-polar	 character	 of	 those	 differences,	 respectively.	 Yang	 et	 al.	 [50]	
divided	the	binding	pocket	of	p38α	used	by	Gleevec®,	Nexavar®	and	BIRB-796	into	a	conserved	hydrophobic	pocket	
(HP)	and	non-conserved	allosteric	pocket	(AP),	comprised	of	two	sites,	and	connected	with	inhibitor’s	selectivity.	In	
this	sense,	we	have	aligned	the	sequences	of	the	three	proteins	with	UCSF	Chimera	[31]	with	the	aim	of	identifying	
residues	in	B-Raf	and	c-Abl	equivalent	to	those	composing	the	HP	and	AP	in	p38α	(see	Figure	1S).	Tables	4S-8S	try	to	
clarify	the	information	provided	by	colouring	residues	from	the	HP	red	and	residues	from	the	AP	blue.	
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B-Raf	
The	 superposition	 of	 the	 experimental	 structure	 of	 B-Raf	 complexed	 with	 Nexavar®	 [35],	 with	 the	 theoretical	
conformations	adopted	by	Nexavar®	and	ligand	7	(Figure	2S),	allows	concluding	that	the	theoretical	pose	is	very	similar	
to	the	experimental	one,	which	suggests	that	the	chosen	methodology	is	suitable.	Besides,	as	expected	taking	into	
account	that	the	placement	stage	was	avoided	during	the	docking	process,	the	common	substructure	has	maintained	
its	position.	
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a)	
	
b)	
	
c)		
	
Figure	3:	Difference	interaction	spectrum	a)	(ligand	7	–	Nexavar®)	for	B-Raf,	b)	(ligand	6	–	Gleevec®)	for	c-Abl	and	c)	
between	Nexavar®,	BIRB-796,	ligand	7	and	ligand	9	with	Gleevec®,	for	p38α	
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(a)	
	
(b)	
	
(c)	
	
(d)	
	
(e)	
	
(f)	
	
	
Figure	4:	Non-polar	and	polar	 contributions	 to	 free	binding	energy	 for	 selected	 residues	of	B-Raf,	 c-Abl	 and	p38α	
interacting	with	different	 ligands.	(a)	and	(b)	correspond	to	non-polar	and	polar	contributions	for	B-Raf	 interacting	
with	 Nexavar®	 and	 ligand	 7,	 respectively.	 (c)	 and	 (d)	 correspond	 to	 non-polar	 and	 polar	 contributions	 for	 c-Abl	
interacting	with	Gleevec®	and	ligand	6.	(e)	and	(f)	correspond	to	non-polar	and	polar	contributions	for	p38α	interacting	
with	Gleevec®,	Nexavar®,	BIRB-796,	ligand	7	and	ligand	9	
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Focussing	 on	 the	 comparison	 between	 ligands	 2	 (IC50	 =	 76.2	 nM)	 and	 7	 (IC50	 <	 1	 nM),	 Figure	 5	 compares	 both	
predicted	structures.	As	seen	in	Table	4S,	B-Raf	establishes	similar	H-bonds	with	both	ligands	(through	GLU501,	CYS532	
and	 ASP594).	 It	 is	 worth	 to	 mention	 the	 H-bond	 network	 established	 by	 ASP594…Nexavar®…GLU501…LYS483,	
previously	described	for	DFG-out	conformations	of	B-Raf	[35],	c-Abl	[34,	51]	and	p38α	[37].	It	is	thus	very	interesting	
to	realise,	see	Figure	3S,	that	a	small	relaxation	of	the	structure	allows	to	increase	the	H-bond	network	to	include	a	H-
bond	between	LYS483	and	ASP594	for	both	Nexavar®	and	ligand	7,	with	lifetimes	of	the	100%	of	the	trajectory	for	all	
H-bonds.	
	 	 	 a)	
	
b)	
	
Figure	5:	Theoretical	structures	of	a)	ligand	2	(Nexavar®)	and	b)	ligand	7	docked	into	B-Raf,	showing	the	protein	with	
worm	radii	proportional	to	the	MMGBSA	predicted	contribution	of	each	residue	to	binding	energy.	
From	a	structural	point	of	view,	therefore,	it	seems	that	the	biggest	difference	between	Nexavar®	and	ligand	7	is	the	
change	 of	 benzene	 with	 naphthalene	 in	 the	 central	 core,	 whose	 bigger	 size	 could	 help	 establishing	 stronger	
interactions	with	the	hydrophobic	pocket.	Figure	3	allows	concluding	on	the	one	hand	that	the	differences	between	
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both	ligands	are	subtle,	and	on	the	other	hand	that	interactions	are	stronger	for	ligand	2	in	the	zone	around	CYS532	
(hinge	region),	and	for	ligand	7	for	the	HP	and	its	surroundings	(VAL471,	VAL482,	VAL528).	Besides,	Figure	4	shows	
that	the	differences	for	CYS532	are	due	to	the	fact	that	Nexavar®	establishes	two	H-bonds	with	CYS532,	while	ligand	
7	can	only	establish	one	H-bond	using	the	oxygen	atom	of	the	morpholine	ring.	Finally,	it	becomes	apparent	that	the	
stronger	 interactions	 for	 residues	 VAL471,	 VAL482	 and	 VAL528	 are	 caused	 by	 the	 change	 from	 benzene	 to	
naphthalene.	From	this	data,	we	suggest	that	a	 ligand	with	naphthalene	in	the	central	core	as	 ligand	7,	but	with	a	
heteroaromatic	moiety	instead	of	the	morpholine	ring	(so	that	it	can	establish	π-π	interactions	with	TRP531),	would	
be	 even	 more	 active	 against	 V600EB-Raf.	 Dietrich	 et	 al.	 [10]	 already	 pointed	 out	 from	 the	 comparison	 between	
compounds	7	and	11	that	favourable	hydrophobic	binding	interactions	were	expected	when	a	naphthyl	ring	is	utilized	
to	bind	the	gatekeeper	region	of	B-Raf.	
c-Abl	
Comparison	of	the	experimental	conformation	adopted	by	Gleevec®	with	the	predicted	one	and	that	of	ligand	6	shows	
the	 common	 substructures	 to	 overlap	 (Figure	 4S),	 while	 the	 1-chloro-2-(trifluoromethyl)benzene	 ring	 of	 ligand	 6	
occupies	a	zone	different	than	that	occupied	by	the	1-methyl-piperazine	ring	of	Gleevec®.Figure	6	allows	to	realise	
that	the	relative	conformation	adopted	by	the	1-chloro-2-(trifluoromethyl)benzene	ring	in	ligand	6	is	precisely	that	
adopted	by	Nexavar®	when	bound	 to	B-Raf.	Also,	as	previously	described	 for	B-Raf,	a	H-bond	network	 formed	by	
ASP381…LIGAND…GLU286…LYS271…ASP381	is	seen	throughout	the	trajectory	(lifetimes	of	more	than	94%,	distances	
~3	Å)	for	both	Gleevec®	and	ligand	6.	It	is	worth	to	emphasize	that	the	recently	discovered	c-Abl	inhibitor	CHMFL-074,	
whose	X-ray	structure	was	solved	with	1.53	Å	of	resolution	(PDB	code	5HU9	[52],	experimental	IC50	=	24	nM)	also	
displays	 the	extended	H-bond	 interaction,	even	 improved	with	an	additional	H-bond	 from	LYS271	 to	GLY383.	The	
superposition	of	the	conformations	adopted	by	the	ligands	docked	into	c-Abl	studied	in	the	present	work	with	that	of	
CHMFL-074	 (Figure	 4S)	 shows	 how	 the	 new	 inhibitor	 includes	 both	 the	 1-methyl-piperazine	 and	 the	 1-chloro-2-
(trifluoromethyl)benzene	rings,	each	ring	located	in	the	same	place	as	the	corresponding	one	for	Gleevec®	and	ligand	
6,	respectively.	The	structural	analysis	from	Figure	6	highlights	the	fact	that	having	a	urea	linker	(ligand	6)	instead	of	
an	acetamide	(Gleevec®)	allows	establishing	2	H-bonds	instead	of	one	between	the	ligand	and	GLU286.	
Besides,	interactions	established	through	the	1-methyl-piperazine	ring	explain	the	better	values	predicted	from	the	
energy	decomposition	analysis	for	residues	VAL289	and	ILE360	in	the	case	of	Gleevec®	(Figure	3).	The	importance	of	
interactions	between	the	1-methyl-piperazine	ring	and	ILE360,	HIS361	and	PHE359	was	highlighted	previously	[10].	
Our	calculations	allow	to	quantify	their	importance.	Thus,	the	H-bond	described	with	ILE360	has	a	lifetime	of	74%	of	
the	trajectory,	while	that	with	HIS361	is	not	predicted	to	be	stable.	PHE359	establishes	indeed	better	interactions	with	
the	1-methyl-piperazine	ring	(Figure	3),	but	the	difference	is	almost	negligible.	Our	results	strongly	suggest	that	the	
key	difference	between	ligand	6	and	Gleevec®	is	the	interaction	with	GLU286,	being	that	difference	almost	exclusively	
of	polar	character	(Figure	4).	Hence,	from	this	data	we	suggest	that	a	structural	modification	of	Gleevec®	or	CHMFL-
074	changing	the	acetamide	linker	with	a	urea	type	one	would	improve	their	c-Abl	inhibition.	The	possibility	of	using	
a	urea	type	linker	was	essayed	by	Dietrich	et	al.	[10],	who	tried	to	improve	compound	4	(IC50	>	30000	nM)	with	the	
urea	linker	(compound	11,	IC50	=	244.0	nM).	
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	 	 	 a)	
	
	 	 	 b)	
	
Figure	6:	Theoretical	structures	of	a)	ligand	1	(Nexavar®)	and	b)	ligand	6	docked	into	c-Abl,	showing	the	protein	with	
worm	radii	proportional	to	the	MMGBSA	predicted	contribution	of	each	residue	to	binding	energy.	
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p38α	
The	analysis	of	the	p38α	sets	now	implies	not	only	the	predicted	conformations	found	for	Gleevec®	(IC50	>	104	nM),	
Nexavar®	(IC50	=	84.8	nM),	BIRB-796	(IC50=4.0	nM),	ligand	7	(IC50	<	1	nM)	and	ligand	9	(IC50	<	1	nM),	but	also	the	
influence	 of	 protein	 structure	 on	 those	 conformations.	 The	 analysis	 of	 the	 superimposed	 ligand	 structures	when	
complexed	with	p38α	(Figure	5S)	confirms	that	the	common	substructure	has	maintained	its	position,	and	shows	the	
conformations	adopted	by	Gleevec®	and	Nexavar®	 in	 the	experimental	structures	 to	be	slightly	different	 from	the	
theoretical	ones.	These	differences	are	higher	for	Nexavar®,	with	the	N-methylformamide	rotated	180°.	Nevertheless,	
the	H-bond	established	between	the	nitrogen	atom	of	the	pyridine	ring	bound	to	N-methylformamide	and	MET109	in	
the	 hinge	 region	 is	 established	 exactly	 the	 same	 way	 for	 both	 structures,	 while	 it	 does	 not	 seem	 that	 the	 N-
methylformamide	establishes	any	interaction	with	the	protein	in	any	of	the	conformations.	
The	influence	of	the	protein	structure	can	be	analysed	by	comparing	the	poses	chosen	for	ligands	1,	7	and	9	when	
docked	into	p38α	Gleevec®,	p38α	Nexavar®	or	p38α	BIRB-796.	As	a	general	trend,	the	conformations	adopted	by	the	
ligands	only	differ	in	that	part	of	the	ligands	interacting	with	the	hinge	region.	That	region	is	formed	by	a	loop	with	
different	structure	for	each	of	the	three	available	protein	structures.	This	can	be	explained	as	a	consequence	of	the	
size	of	the	ligand	docked	in	each	X-Ray	structure.	Thus,	the	conformation	adopted	by	Gleevec®	when	docked	into	p38α	
Nexavar®	scores	the	worst	(Table	2),	as	a	consequence	of	steric	hindrance:	in	this	case,	the	hinge	region	would	clash	
with	the	pyridine	ring	because	the	hinge	region	was	originally	accommodating	a	smaller	ligand.	As	for	ligand	7	(see	
Figure	6S),	we	see	that	the	hinge	region	is	too	far	for	p38α	Gleevec®	and	the	best	interactions	(with	a	H-bond	with	
GLY110)	are	obtained	for	the	p38α	BIRB-796	structure,	which	could	be	expected	realising	that	the	protein	structure	
has	the	hinge	region	adapted	for	the	morpholine	ring	shared	by	BIRB-796	and	ligand	7.	This	trend	is	reproduced	in	
Table	2,	where	ligand	7	is	ranked	best	for	p38α	BIRB-706.	
All	these	results	emphasize	the	importance	of	the	hinge	region	of	p38α,	even	lacking	a	defined	secondary	structure.	
Thus,	in	order	to	take	into	account	the	structure	of	the	hinge	region,	we	will	compare	the	predicted	structure	for	ligand	
1	docked	 into	p38α	Gleevec®,	 ligand	2	docked	 into	p38α	Nexavar®,	 ligand	3	docked	 into	p38α	BIRB-796,	 ligand	7	
docked	into	p38α	BIRB-796	structure,	and	ligand	9	docked	into	p38α	Nexavar®	(Figure	7).	
The	experimental	structures	of	Gleevec®,	Nexavar®	and	BIRB-796	docked	into	p38α	[36,	37]	share	an	interaction	with	
the	hinge	region	through	a	H-bond	with	MET109,	and	a	H-bond	network	between	ASP168…ligand…GLU71.	As	reported	
before	for	the	B-Raf	and	c-Abl	sets,	our	predicted	structures	suggest	an	extension	of	this	H-bond	network,	this	time	
just	to	the	conserved	LYS53	(see	Figure	7S).	Our	modelled	BIRB-796	ligand	docked	into	p38α	allows	us	to	propose	a	
distinct	feature,	through	a	non-conserved	TYR35	in	the	AP	zone	that	expands	that	H-bond	network	through	a	H-bond	
with	one	of	the	urea	NH	groups.	This	 implies	that	changing	urea	with	acetamide	would	worsen	 its	p38α	inhibition	
properties	because	another	NH	group	is	needed	to	establish	a	H-bond	with	GLU71.	
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a)	
	
b)	
	
c)	
	
d)	
	
e)	
	
	
	
Figure	7:	Theoretical	structure	for	a)	Gleevec®,	b)	Nexavar®,	c)	BIRB-796,	d)	ligand	7	and	e)	ligand	9,	docked	into	p38α	
showing	the	protein	with	worm	radii	proportional	to	the	MMGBSA	predicted	contribution	of	that	residue	to	binding	
energy.		
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An	analysis	from	an	energetic	point	of	view	(Figures	3	and	4)	focus	our	attention	on	residues	LYS53,	THR106,	HIS148	
and	LEU167.	As	for	LYS53,	differences	arise	from	polar	terms,	so	that	the	polar	contribution	of	LYS53	for	binding	to	
BIRB-796	or	ligand	7	favours	binding,	while	for	the	other	ligands	it	does	not.	This	can	be	connected	with	the	different	
conformation	adopted	by	LYS53	and	the	DFG	motif	when	ligands	3	and	7	are	docked,	compared	to	the	conformation	
when	the	docked	ligands	are	1,	2	or	9.	Figure	8,	which	compares	those	conformations	for	Gleevec®	and	ligand	7,	shows	
how	Gleevec®	can	establish	more	interactions	with	the	DFG	motif,	although	it	seems	that	at	cost	of	 increasing	the	
electrostatic	repulsion	with	the	ligand	(∆𝐻-,-8 	=	12.9	kcal	mol-1	for	Gleevec®	versus	3.1	kcal	mol-1	for	BIRB-796).		
THR106	establishes	an	already	described	H-bond	with	the	ligand	[36]	(see	Table	6S)	that	can	explain	its	better	polar	
contributions	to	binding.	Differences	for	LEU167	seem	mainly	related	to	non-polar	terms,	while	for	HIS148	Gleevec®	
is	the	only	ligand	for	which	polar	terms	favour	binding.	This	can	be	explained	because	the	1-methyl-piperazine	ring	in	
Gleevec®	is	able	to	establish	favourable	electrostatic	interactions	with	HIS148	(-12.4	kcal	mol-1	for	Gleevec®	versus	-
1.34	kcal	mol-1	for	Nexavar®).	All	these	results	point	first	to	the	need	to	investigate	further	on	the	dynamics	of	p38α	
to	shed	 light	 into	the	 importance	of	 the	LYS53	and	hinge	region	conformations	and	how	they	adapt	 to	the	size	of	
different	 ligands,	which	escapes	the	scope	of	the	present	work.	Second,	 it	seems	that	one	of	the	reasons	why	the	
binding	of	Gleevec®	to	p38α	is	weak	is	the	use	of	acetamide	instead	of	urea	as	linker.	Finally,	although	the	total	positive	
charge	of	Gleevec®	could	be	another	of	the	reasons	for	 its	weak	binding	to	p38α,	our	results	point	to	the	need	to	
explore	the	possibility	of	expanding	the	favourable	interaction	between	the	1-methyl-piperazine	ring	and	HIS148	with	
a	non-charged	heterocycle	possessing	a	H-bond	donor	feature.	
	
Figure	8:	Superposition	of	complexes	of	p38a	with	Gleevec®	(light	brown)	and	ligand	7	(green)	showing	the	different	
conformation	adopted	by	LYS53	and	the	DFG	motif	(highlighted	in	dark	orange)	
Conclusion	
This	work	 analyses	 the	 possibility	 of	 improving	 a	 docking	 procedure	 specially	 designed	 for	 a	 congeneric	 series	 of	
compounds	by	means	of	a	re-scoring	of	the	initial	binding	poses	through	the	MMPB(GB)SA	methodology,	essaying	a	
set	of	different	options	within	the	methodology	on	an	ensemble	of	eleven	ligands	bound	to	the	B-Raf,	c-Abl	and	p38α	
kinases.	Our	results	allow	us	to	conclude	that	post	processing	is	in	general	a	good	practice	to	be	followed	as	it	enhances	
the	quality	of	the	results	at	a	relatively	low	computational	cost.	Although	it	is	out	of	any	doubt	that	a	post	processing	
using	MMPB(GB)SA	with	a	long	MD	trajectory	is	expected	to	give	better	results	in	a	broad	range	of	situations,	it	is	clear	
also	from	our	results	that	a	rational	comparison	of	quicker	options,	having	in	mind	that	results	are	case-dependent,	
can	improve	these	results	requiring	much	less	resources.	This	can	be	of	great	importance	when	the	set	to	be	analysed	
is	big.	In	this	sense,	for	the	sets	studied	in	this	work,	short	MD	runs	do	not	always	provide	better	results,	which	also	
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happens	with	the	inclusion	of	entropy.	As	the	treatment	of	solvent	is	concerned,	there	is	consensus	in	that	GB=2	is	
better	than	GB=5,	and	also	in	that	a	previous	analysis	of	different	options	for	εi	is	advisable.		
The	analysis	of	the	different	scoring	parameters	obtained	has	allowed	us	to	choose	the	best	method	for	each	of	the	
studied	proteins.	The	total	charge	of	the	proteins	studied	(B-Raf	+9,	c-Abl	-6	and	p38α	-3)	and	the	binding	strength	of	
positively	charged	ligands	can	be	correlated	to	propose	as	a	qualitative	rule	that	positively	charged	weak	binders	need	
a	high	dielectric	constant	to	be	correctly	scored	when	binding	to	a	positively	charged	protein,	while	they	need	a	low	
dielectric	constant	when	binding	to	a	negatively	charged	protein.	We	would	thus	propose	as	an	a	priori	protocol	to	
use	the	one-snapshot	MMPBSA	post-processing	methodology,	with	appropriate	εi	and	no	entropic	term.	Hence,	we	
have	analysed	the	proposed	docked	structures	from	structural	and	energetic	points	of	view	focussing	in	those	ligands	
that	are	predicted	experimentally	 to	bind	 strongly	 to	each	of	 the	proteins,	 in	order	 to	discern	which	 features	are	
required	to	propose	further	modifications	that	would	improve	them.	Thus,	for	B-Raf	we	suggest	that	ligand	7	with	an	
heteroaromatic	moiety	instead	of	the	morpholine	ring	would	be	even	more	active,	while	a	modification	of	Gleevec®	
changing	the	acetamide	linker	with	a	urea	type	one	would	improve	its	c-Abl	inhibition.	Finally,	our	protocol	allows	us	
to	conclude	that	the	urea	linker	is	also	important	for	p38α	inhibition,	and	that	the	possibility	of	changing	the	1-methyl-
piperazine	ring	with	a	non-charged	heterocycle	that	can	donor	a	H-bond	to	HIS148	could	be	an	interesting	route	to	be	
explored.	
Future	perspective	
There	exists	a	clear	interest	in	develop	new	kinase	inhibitors.	The	increase	in	available	simulation	timescales	through	
potent	GPUs	together	with	new	sampling	methodologies	like	Gaussian	Accelerated	Molecular	Dynamics	are	expected	
to	find	new	allosteric	pockets	that	will	allow	researchers	to	propose	potent	type	III	kinase	inhibitors.	
Summary	points	
• Re-scoring	 after	 a	 docking	 procedure	 is	 a	 computationally	 cheap	 and	 useful	methodology	 to	 improve	 the	
quality	of	results	
• Using	 just	 one	 snapshot	 within	 the	 MMPB(GB)SA	 methodology,	 together	 with	 a	 rational	 comparison	 of	
different	parameters,	could	be	as	useful	as	a	long	MD	run	
• When	the	set	to	be	studied	is	big	an	a	priori	protocol	would	be	to	use	one	snapshot	MMPBSA	with	no	entropic	
term	and	choose	εi	according	to	the	charge	of	protein	and	ligands	
• B-Raf	could	be	increased	modifying	ligand	7	with	an	heteroaromatic	moiety	instead	of	the	morpholine	ring	
• c-Abl	inhibition	could	be	increased	modifying	Gleevec®	by	changing	the	acetamide	linker	with	a	urea	type	one	
• p38α	inhibition	could	be	increased	by	changing	the	1-methyl-piperazine	ring	with	a	non-charged	heterocycle	
being	able	to	establish	an	H-bond	with	HIS148	
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